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and A. J. Man in ’t Veld. Catecholamine handling in the
porcine heart: a microdialysis approach. Am. J. Physiol. 277
(Heart Circ. Physiol. 46): H1562–H1569, 1999.—Experimen-
tal findings suggest a pronounced concentration gradient of
norepinephrine (NE) between the intravascular and intersti-
tial compartments of the heart, compatible with an active
neuronal reuptake (U1) and/or an endothelial barrier. Using
the microdialysis technique in eight anesthetized pigs, we
investigated this NE gradient, both under baseline conditions
and during increments in either systemic or myocardial
interstitial fluid (MIF) NE concentration. At steady state,
baseline MIF NE (0.9 6 0.1 nmol/l) was higher than arterial
NE (0.3 6 0.1 nmol/l) but was not different from coronary
venous NE (1.5 6 0.3 nmol/l). Local U1 inhibition raised MIF
NE concentration to 6.5 6 0.9 nmol/l. During intravenous NE
infusions (0.6 and 1.8 nmol ·kg21 ·min21), the fractional re-
moval of NE by the myocardium was 79 6 4% to 69 6 3%,
depending on the infusion rate. Despite this extensive re-
moval, the quotient of changes in MIF and arterial concentra-
tion (DMIF/DA ratio) for NE were only 0.10 6 0.02 for the
lower infusion rate and 0.11 6 0.01 for the higher infusion
rate, whereas U1 blockade caused the DMIF/DA ratio to rise
to 0.21 6 0.03 and 0.36 6 0.05, respectively. From the
differences in DMIF/DA ratios with and without U1 inhibi-
tion, we calculated that 67 6 5% of MIF NE is removed by U1.
Intracoronary infusion of tyramine (154 nmol ·kg21 ·min21)
caused a 15-fold increase in MIF NE concentration. This
pronounced increase was paralleled by a comparable increase
of NE in the coronary vein. We conclude that U1 and
extraneuronal uptake, and not an endothelial barrier, are the
principal mechanisms underlying the concentration gradient
of NE between the interstitial and intravascular compart-
ments in the porcine heart.
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SEVERAL EXPERIMENTAL FINDINGS suggest that in the
heart a pronounced concentration gradient for norepi-
nephrine (NE) exists between the interstitial and intra-
vascular compartments. Silverberg et al. (31) showed
that the coronary sinus NE concentration induced by
an NE infusion that led to only a small increase in the
heart rate was eight times higher than that induced by
stellate ganglion stimulation that caused a similar
increase in heart rate. From tracer dilution experi-
ments Cousineau et al. (8) estimated a ratio of 15%
between the interstitial and arterial compartments in
canine hearts. More recently, Obst et al. (29), using
ultrafiltration of interstitial fluid from isolated per-
fused rat hearts, found ratios of interstitial transudate
to arterial concentrations of NE of 0.14 to 0.77, depend-
ing on the concentration of NE administered. These
investigators interpreted these findings as suggesting
that the neuronal uptake of NE is the most important
determinant for maintaining a concentration gradient
between the circulatory and interstitial compartments.
Because of the dense sympathetic innervation, espe-
cially in the heart, neuronal reuptake (U1) of NE could
be an important determinant for maintaining such a
gradient (17, 19). However, other investigators have
suggested that the concentration gradient is caused by
a physical barrier of the blood vessel wall as well (7, 8,
25, 29, 30, 33).
A profound understanding of catecholamine kinetics
is invaluable when interpreting catecholamine data
and their representation of sympathetic activity. Using
the isotope dilution method and arteriovenous sam-
pling, Esler et al. (16) introduced regional spillover as a
kinetic parameter that aims to reflect the rate of NE
entering the circulation rather than true production. In
a recent study, Kopin et al. (22) have modified this
technique and introduced a new method to estimate
neuronal release that is based on the measurements of
the specific activities of radiolabeled NE and its extra-
neuronal metabolite, normetanephrine, in plasma. Neu-
ronal release of NE into the interstitial space is esti-
mated as the sum of the spillover of NE from the
interstitium to the circulation and the uptake of re-
leased NE from the interstitium. Nonetheless, the
interstitial compartment can only be monitored either
by estimation through the application of mathematical
kinetic modeling or with the use of in vitro or semi-in
vivo preparations. The microdialysis technique, how-
ever, allows for the accurate estimation of the concentra-
tion of catecholamines in the myocardial interstitial
fluid (MIF) in vivo (15, 18, 32, 37). The technique
should allow for measurement of the hitherto unquanti-
fiable amount of NE that is released but taken up
before reaching the vascular compartment, thus filling
the gaps in existing kinetic models.
In a series of experiments in which either the circula-
tory or the interstitial NE concentration was increased,
we investigated how the concentration of NE in the
MIF is related to its concentration in the arterial and
coronary venous circulation. The importance of U1 and
extraneuronal uptake to this relationship was explored
by adding desipramine [desmethylimipramine (DMI)],
a well-known U1 inhibitor, to the dialysate of one of the
microdialysis probes and performing experiments with
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isoproterenol (Iso), a catecholamine that is not handled
by U1. Furthermore, NE concentrations in MIF, arte-
rial plasma, and the coronary effluent at baseline and
during infusion of NE provided an estimate of spillover,
uptake, and release of NE.
METHODS
Animal care. All experiments were performed in accor-
dance with both the ‘‘Guiding Principles for Research Involv-
ing Animals and Human Beings’’ as approved by the Council
of the American Physiological Society and the regulations of
the Animal Care Committee of the Erasmus University of
Rotterdam (The Netherlands).
Surgical procedure. After an overnight fast, crossbred
Landrace 3 Yorkshire pigs of either sex (30–35 kg, n 5 8)
were sedated with ketamine (Ketalin; 20–25 mg/kg im) and
anesthetized with pentobarbital sodium (Narcovet; 20 mg/kg
iv). The animals were intubated and connected to a respirator
for intermittent positive-pressure ventilation with a mixture
of oxygen and nitrogen. Respiratory rate and tidal volume
were set to keep arterial blood gases within the normal
ranges: pH between 7.35 and 7.45, PCO2 between 35 and 45
mmHg, and PO2 between 100 and 150 mmHg.
Catheters were positioned in the superior caval vein for
continuous administration of pentobarbital sodium (10–15
mg·kg21 ·h21) and Haemaccel for replacement of blood with-
drawn during sampling. In the descending aorta, a fluid-filled
catheter was placed for monitoring of aortic blood pressure
and for withdrawal of blood samples. Through the left carotid
artery a micromanometer-tipped catheter (B. Braun Medical,
Uden, The Netherlands) was inserted into the left ventricle
for measurement of left ventricular pressure and, by electri-
cal differentiation, the maximum of its first derivative (LV
dP/dtmax). After pancuronium bromide (Pavulon; 4 mg) was
administered, a midsternal thoracotomy was performed, and
the heart was suspended in a pericardial cradle. An electro-
magnetic flow probe (Skalar, Delft, The Netherlands) was
then placed around the ascending aorta for measurement of
aortic blood flow (cardiac output). A proximal segment of the
left anterior descending coronary artery (LAD) was dissected
free for placement of a Doppler flow probe. Distal to this site,
a small cannula (1.3-mm outer diameter) was inserted into
the LAD for the administration of tyramine.
The microdialysis catheters were implanted in the tissue
with the help of a steel guiding needle and split plastic tubing.
Three microdialysis probes were inserted into the left ventricu-
lar myocardium: one in the region of the left circumflex
coronary artery (LCX) and two in the area perfused by the
LAD. To achieve local U1 inhibition, one of the LAD probes
was coperfused with DMI (100 µM) (36). In addition, microdi-
alysis probes were placed in the right carotid artery and the
anterior interventricular coronary vein that drains the terri-
tory perfused by the LAD.
Dialysis methodology. For microdialysis, CMA/20 probes
(Carnegie Medicine, Stockholm, Sweden) were used. The
polycarbonate dialysis membrane of these probes has a cutoff
value of 20 kDa, a length of 10 mm, and a diameter of 0.5 mm.
The probes were perfused with an isotonic Ringer solution at
a rate of 2 µl/min using a CMA/100 microinjection pump.
Dialysate volumes of 20 µl (sampling time 10 min) were
collected in microvials containing 20 µl of a solution of 2%
(wt/vol) EDTA and 150 nM Epinine as internal standard in
0.08 N acetic acid. Sampling was started immediately after
the catheters were inserted. The plasma samples were drawn
into chilled heparinized tubes containing 12 mg of glutathi-
one, and, like the microdialysis samples, stored at 280°C and
analyzed within the next 5 days (5).
Determination of in vivo probe recovery. Probe recovery is
defined as the quotient of dialysate catecholamine concentra-
tion and the actual catecholamine concentration in the me-
dium that is dialyzed. In vivo probe recovery was determined
separately for blood as well as myocardial intercellular fluid.
Probe recovery for blood was estimated by comparing catechol-
amine concentrations in plasma with catecholamine concen-
trations in the corresponding dialysate of the microdialysis
probe in the carotid artery (Fig. 1).
Recovery of NE for the probes in the myocardium was
estimated by applying the retrodialysis method. This method
relies on the assumptions that diffusion of a substance into
the microdialysis probe equals the outward diffusion and that
the diffusion characteristics of the calibrator match those of
the analyte (Fig. 2) (24, 35). Furthermore, this method will
only provide an estimation of the concentration of the analyte
at the outer membrane of the microdialysis probe, rather
Fig. 1. Determination of in vivo recovery for isoproterenol (Iso; top)
and norepinephrine (NE; bottom): arterial microdialysis vs. arterial
sampling. Dotted lines indicate 95% confidence limits. Data are
presented as 17 data points for 7 animals.
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than the mean interstitial concentration. Ideally, although
the calibrator should not have any pharmacodynamic effects,
both substances should have the same pharmacokinetic
properties. Consequently, the concentration of the calibrator
in the perfusate should be as low as possible to prevent any
significant influence on the metabolism of the analyte, e.g.,
saturation of active uptake mechanisms such as U1.
In this study l-erythro-a-methylnorepinephrine (AMN) was
chosen as the calibrator for probe recovery for NE. This AMN
isomer is considered to be a ‘‘false transmitter’’; it is handled
like NE, although it does not share its pharmacodynamic
effects. Retrodialysis was performed in four animals for the
length of the whole experiment. The average percentage of
loss of AMN, i.e., in vivo probe recovery for NE in MIF, was
based on the data derived from the LAD and LCX probes of all
four animals. This method revealed a probe recovery of 52 6
1% (2 probes in 4 animals). Comparison of the concentration
of NE in arterial plasma with the NE concentration in the
dialysate obtained from the probe positioned in the carotid
artery showed a similar value for probe recovery of NE (52 6
4%, Fig. 1). For Iso, using a similar approach, the in vivo
probe recovery was 37 6 3% (Fig. 1).
Protocol. After 120–150 min, steady-state conditions were
reached at baseline. Thereafter, NE and Iso were intrave-
nously infused consecutively for 30 min for each dose, fol-
lowed by a 30-min intracoronary infusion of tyramine. After
each infusion, a 30-min stabilization period was introduced,
allowing for a complete washout of the infused substances
and return to baseline conditions. The infusion rates of Iso
(0.16 and 0.48 nmol · kg21 · min21) and tyramine (154
nmol ·kg21 ·min21) were chosen to correspond with the hemo-
dynamic response of the NE infusions (0.6 and 1.8
nmol ·kg21 ·min21) (21). At the end of the experiments, the
pigs were killed with an overdose of pentobarbital.
Analytic procedure. Plasma catecholamines were deter-
mined by HPLC with fluorimetric detection after liquid-liquid
extraction and derivatization with the fluorogenic agent
N,N8-diphenylethylenediamine (DPE) (34). For microdialysis
samples, the catecholamines were not extracted before fluori-
metric detection with HPLC but were directly derivatized
according to the procedure described by Alberts et al. (3). This
method suppresses the interference of in vivo factors on
derivatization, thereby improving sensitivity.
Reagents and pharmaceuticals. Ketalin and Narcovet were
obtained from Apharmo (Arnhem, The Netherlands), Pavulon
from Organon Teknica (Boxtel, The Netherlands), Ringer
solution from Baxter (Uden, The Netherlands), Haemaccel
from Behringwerke (Marburg, Germany), and Epinine from
Zambon (Milan, Italy). Tyramine, NE, and Iso for infusions
were obtained from the Department of Pharmacy (University
Hospital, Rotterdam, The Netherlands). DMI, bicine, NE, and
AMN were purchased from Sigma (St. Louis, MO); EDTA,
N-ethylmaleimide (NEM), and hydrochloric acid were from
Merck (Darmstadt, Germany); potassium ferricyanide was
from Aldrich (Bornem, Belgium); L-glutathione was from
Fluka (Buchs, Switzerland); and acetic acid and acetonitrile
were from Baker (Deventer, The Netherlands). DPE was
prepared as reported previously (34).
Statistics and calculations. Results are expressed as
means 6 SE. NE and Iso concentrations obtained with
microdialysis were corrected for probe recovery. Baseline
values were determined by averaging the data from the
steady state before the infusions. During the infusions of NE
and Iso, the cardiac extraction (E) was calculated as
E (%) 5
DA 2 DV
DA
· 100 (1)
where DA and DV are the changes from baseline of arterial
and coronary venous concentrations, respectively. The ratio of
interstitial NE to arterial plasma NE is presented as
DMIF/DA ratio 5
DMIF
DA
(2)
where DMIF is the change from baseline of the myocardial
interstitial fluid concentration.
The percentage of NE that can be recovered from the MIF
and taken up by U1 (FxU1) can be calculated from the
difference between the DMIF/DA ratio with and without U1
inhibition as
Fx U1 (%) 5
DMIF/DADMI 2 DMIF/DA
DMIF/DADMI
· 100 (3)
where DMIF/DADMI is the DMIF/DA ratio with U1 inhibition.
The percentage of MIF NE that is originating from the
circulation (MIF NEA) at baseline can be estimated as follows
MIF NEA (%) 5
DMIF/DA ratio · NEA
NEMIF
· 100 (4)
where NEA and NEMIF are the baseline NE concentrations in
arterial plasma and MIF, respectively.
Although no radiolabeled material was used in the present
study, the method introduced by Kopin and colleagues (22)
can still be applied to estimate neuronal release by replacing
the specific activity of radiolabeled NE with the ratio of
changes from baseline of the NE concentration in arterial and
coronary venous plasma (RA and RV, respectively) and MIF
(RMIF) during systemic infusion of NE. The use of this ratio is
based on the assumptions that endogenous NE is reflected by
the baseline NE concentration and that the change in its
release is negligible compared with the change in NE concen-
trations induced by infused NE. According to these revised
equations, spillover (SO) can be calculated as
SO 5 Q · NEA · (1 2 E) · 31RARV2 2 14 (5)
Fig. 2. Diagram of retrodialysis method for determination of in vivo
recovery. CA, concentration of calibrator A; CB, concentration of
analyte B; FxAout, fraction of calibrator A that has diffused out of
perfusate into medium; FxBin, fraction of analyte B that has diffused
out of medium into dialysate, i.e., recovery of analyte B.
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where Q is the coronary plasma flow (CPF) that is calculated
from the coronary blood flow and the hematocrit, which was
estimated using the plasma hemoglobin concentration. The
uptake of released NE (Ur) from the interstitium can be
estimated by using RMIF in an analogous equation
Ur 5 Q · NEA · E · 31 RARMIF2 214 (6)
As mentioned in the introduction, the sum of Eqs. 5 and 6
provides an estimation of the neuronal release rate (Rr)
Rr 5 SO 1 Ur (7)
Subsequently, the ratio of uptake of released NE and neuro-
nal release can be used as to measure the efficiency of total
uptake (EffU)
EffU (%) 5
Ur
Rr
· 100 (8)
For statistical analysis, two-way ANOVA, one-way ANOVA
for repeated measures with Dunnett’s multiple-comparison
test as a post hoc test, Student’s t-test, and linear regression
analysis were used as appropriate.
RESULTS
NE infusions. Steady-state concentrations of MIF
NE were observed 120–150 min after the probes were
placed and microdialysis was started. The baseline
arterial plasma NE concentration was about three
times lower than the MIF NE concentration (P , 0.001,
Fig. 3). MIF NE concentrations in the LAD and LCX
regions were similar, and values did not differ from
those in the coronary vein. During U1 blockade, MIF
NE concentration increased more than sixfold (P ,
0.01, Fig. 3).
Circulatory and MIF NE concentrations at 20 and 30
min after the start of both systemic NE infusions did
not differ, suggesting that a steady state was reached
within 20 min (Fig. 3). The extraction of arterially
delivered NE was 79 6 4% and 69 6 3% for the low and
high infusion rates, respectively. Without U1 blockade,
the MIF NE concentration (LAD and LCX regions)
remained considerably lower than the arterial and
coronary venous NE concentrations. During U1 block-
ade, however, the MIF NE concentration value was
between the arterial plasma and coronary venous con-
centration values (Table 1 and Fig. 3). Without U1
blockade, the DMIF/DA ratio (Eq. 2) was 0.10 6 0.01 for
the lower infusion rate and 0.11 6 0.01 for the higher
NE infusion rate, whereas DMI caused the DMIF/DA
ratio to rise to 0.21 6 0.02 and 0.36 6 0.05, respectively
(P , 0.05).
Spillover, rate of uptake, rate of neuronal release,
and the efficiency of uptake at baseline were calculated
from the data of both NE infusions using Eqs. 5–8.
Despite the large increment in circulatory NE and MIF
NE concentrations, represented by the ratios of DNE
values to baseline between the lower and higher NE
doses, the kinetic parameters for NE remained un-
changed (Table 2).
Systemic infusions of NE caused a marked dose-
dependent increase in heart rate, blood pressure, coro-
nary blood flow, and LV dP/dtmax (Table 3). The relation-
ship between changes in LV dP/dtmax and MIF NE
concentration was much steeper than the relationship
between changes in LV dP/dtmax and arterial NE concen-
tration (P , 0.001, Fig. 4).
Isoproterenol infusions. Systemic Iso infusions caused
dose-dependent increments in arterial and venous Iso
concentrations (Fig. 3 and Table 1). Circulatory and
MIF Iso concentrations at 20 and 30 min after the start
of both systemic Iso infusions did not differ signifi-
cantly, suggesting that a steady state was reached
within 20 min (Fig. 3). The extraction of arterially
delivered Iso in the coronary circulation was 24 6 5%
with both the low and the high infusion rates. MIF Iso
concentrations were lower than arterial and coronary
venous concentrations, and values did not alter in the
presence of U1 blockade. The DMIF/DA ratio for Iso was
0.37 6 0.02 with the low infusion rate and 0.34 6 0.02
with the high infusion rate.
Isoproterenol infusions caused dose-dependent incre-
ments in heart rate, systolic blood pressure, coronary
Fig. 3. NE (left) and Iso concentrations
(right) during successive intravenous
infusions of NE and Iso. l, Carotid
artery; n, coronary vein; r, myocardial
interstitial fluid (MIF) left anterior de-
scending coronary artery (LAD) region;
s, MIF LAD region under neuronal
uptake (U1) blockade; 3, MIF left cir-
cumflex coronary artery (LCX) region.
Data are presented as means 6 SE for 8
animals.
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blood flow, and LV dP/dtmax and a dose-dependent
decrease in diastolic blood pressure (Table 2). The slope
of the regression line of the relationship between LV
dP/dtmax (%change) and Iso concentration was 46 6 21
for MIF Iso and 13 6 8 for arterial Iso concentrations.
Tyramine infusion. Tyramine, like NE, is taken up by
neurons through U1, and it subsequently displaces NE
from the nerve terminals because of its higher affinity
for the neuronal storage proteins (37). Consequently,
the degree of attenuation of tyramine-induced NE
release is a measure of the degree of U1 blockade.
Without U1 blockade, infusion of tyramine in the LAD
caused a 15-fold rise in the MIF NE concentration in
the LAD region, accompanied by a similar increase of
the NE concentration in the coronary vein (Fig. 5).
Under U1 blockade, this response was almost com-
pletely abolished, indicating that the blockade of U1
was virtually complete with the dose of DMI used.
Tyramine infusion in the LAD was also associated with
a fivefold increase in the MIF NE concentration in the
LCX region. Because the systemic arterial NE concen-
tration also slightly increased during intracoronary
tyramine infusion, this increase was most likely caused
by overflow of tyramine from the coronary into the
systemic circulation. The hemodynamic response to
tyramine was mainly confined to the heart; LV dP/dtmax
increased almost threefold to 3,933 6 465 mmHg/s,
comparable to the increase seen during the infusions of
NE and Iso.
DISCUSSION
We investigated to what extent the concentration of
NE in the myocardial intercellular space was related to
its concentration in the arterial and coronary venous
circulation at baseline and after increments in plasma
or interstitial NE concentration induced by either
systemic infusions of NE or an intracoronary infusion
of tyramine. In addition, the importance of the U1
mechanism for the MIF NE concentration was assessed
by perfusing one of the probes with the U1 inhibitor
DMI and performing studies with Iso, a catecholamine
that is not handled by U1. Finally, adaptation of the
method introduced by Kopin et al. (22) provided an
estimate of spillover, uptake, and, consequently, release
of NE.
In agreement with the results of other studies using
the microdialysis technique, steady-state MIF NE con-
centrations were observed 120–150 min after the probes
were inserted and microdialysis was started. Basal
MIF NE concentrations measured in this study were
similar to those reported by Akiyama et al. (1, 2), who
performed microdialysis in feline hearts. At baseline,
MIF NE concentrations in the LCX and LAD regions
were similar, suggesting no important regional differ-
ences in myocardial sympathetic activity. In contrast to
various other microdialysis studies that reported arte-
rial plasma levels at baseline to be similar to or even
higher than interstitial NE levels (1, 27, 28), MIF NE
concentrations in the present study were three times
higher than arterial plasma concentrations. These re-
sults are in keeping with estimates made in other
studies reporting that the concentration of NE at sites
of release is about three- to fivefold higher than in
plasma (10, 23, 26). This concentration gradient is the
driving force behind the exchange of NE from the
interstitial compartment to the circulation. Accord-
ingly, one would expect this gradient to be reflected in
somewhat higher NE concentrations in MIF than in the
coronary vein. In contrast, NE concentrations in the
coronary vein were similar to those in MIF, both under
baseline conditions and during intracoronary infusion
of tyramine, which induced a 15-fold increase in the
MIF NE concentration. A possible explanation for this
unexpected finding is that the NE concentration mea-
Table 1. Comparison of increments of circulatory
and interstitial concentrations of norepinephrine
and isoproterenol during intravenous infusions
of norepinephrine or isoproterenol
Location of
Concentration
Norepinephrine Infusion,
nmol ·kg21 ·min21
Isoproterenol Infusion,
nmol ·kg21 ·min21
0.6 1.8 0.16 0.48
Carotid artery,
nmol/l 10.660.8 28.262.1 4.960.8 9.262.1
Coronary vein,
nmol/l 2.760.8 9.661.6 3.660.6 6.961.1
E, % 7964 6963 2465 2364
MIF LAD,
nmol/l 1.160.2 3.160.3 1.860.3 3.160.5
MIF
LAD1DMI,
nmol/l 2.160.5 11.262.9† 1.860.2 3.160.4
MIF LCX,
nmol/l 1.360.2 3.660.3 1.960.3 3.460.5
DMIF/DA 0.1060.01 0.1160.01 0.3760.02 0.3460.02
DMIF/DA1
DMI 0.2160.03* 0.3660.05† 0.3760.03 0.3560.02
Values are means 6 SE of norepinephrine or isoproterenol concen-
trations. E, cardiac arteriovenous extraction of norepinephrine; MIF,
myocardial interstitial fluid; LAD, left anterior descending coronary
artery; DMI, desipramine; LCX, left circumferential coronary artery;
DMIF/DA, quotient of change in interstitial and arterial concentra-
tions. *P , 0.05, †P , 0.01 compared with value in same location in
absence of DMI.
Table 2. Spillover, uptake, and release
of norepinephrine at baseline derived
from data compiled during systemic
intravenous infusions of norepinephrine
Norepinephrine Infusion,
nmol ·kg21 ·min21
0.6 1.8
RA 59.168.2 155.3622
RV 1.860.3 6.960.6
RMIF 1.360.2 3.860.5
SO, pmol/min 35.165.6 38.865.4
Ur, pmol/min 194.1633.4 203.7650.8
Rr, pmol/min 229.3636.8 242.5653.4
EffU, % 8462 79.062
Values are means 6 SE. RA, ratio of change in norepinephrine
(DNE) values to baseline for arterial plasma; RV, ratio of DNE values
to baseline for coronary effluent; RMIF, ratio of DNE values to baseline
for MIF; SO, spillover; Ur, NE uptake from interstitium; Rr, rate of
neuronal release; EffU, efficiency of uptake of locally released NE.
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sured around the membrane of the microdialysis probe
underestimated to some extent the concentration of NE
at sites of release.
The observed absence of an NE gradient between the
MIF and coronary vein does not support previous
suggestions of the existence of an endothelial barrier
for the diffusion of NE from the interstitial to the
intravascular compartment (7, 25, 29, 30, 33). The
presence of such an endothelial barrier could provide
an explanation for the well-known difference in the
relation of blood pressure response and plasma NE
concentration observed for exogenously administered
NE or for tyramine-induced endogenously released NE
(4, 6). If an endothelial barrier for the diffusion of NE is
present, MIF NE concentration and the NE concentra-
tion in the coronary vein, as a reflection of the NE
concentration in the myocardial capillaries, should be
different. However, both at baseline and during infu-
sion of tyramine through the LAD, MIF NE concentra-
tions in the LAD region and coronary vein were similar,
indicating an unhindered exchange of endogenous NE
from the interstitial to the vascular compartments. The
considerable gradient between NE concentrations in
the coronary vein and MIF that was seen during
systemic infusion of NE was absent under U1 blockade
and therefore is attributable to U1. Thus no endothelial
barrier to the diffusion of NE appears to be present in
the porcine heart.
Experimental studies and studies in humans with
the use of labeled infusions of NE have shown that
60–80% of arterially delivered NE is removed by the
myocardium (11, 13, 19). With the use of unlabeled NE
in the present study, the extraction of NE ranged from
79 to 69%, depending on the infused dose (Table 1).
Notwithstanding this high fractional removal, the MIF
NE concentration remained extremely low as reflected
by a DMIF/DA ratio of ,0.10. This value is close to the
MIF/A ratio of 0.15 reported for the canine myocardium
by Cousineau et al. (8) using the capillary-interstitium
concentration model developed by Ziegler and Goresky
(38). The important role of U1 in the removal of NE
from the MIF was confirmed by comparing the MIF NE
concentrations in the microdialysis probes in the LAD
region with and without the U1 inhibitor DMI. Al-
Table 3. Comparison of cardiac and systemic hemodynamics during systemic
intravenous infusions of norepinephrine and isoproterenol
Norepinephrine Infusion,
nmol ·kg21 ·min21
Isoproterenol Infusion,
nmol ·kg21 ·min21
Baseline 0.6 1.8 Baseline 0.16 0.48
HR, beats/min 12068 12767 14165† 12566 18264† 19767†
SAP, mmHg 10364 12164† 13765† 9765 10665* 11265†
DAP, mmHg 7265 8564† 9365† 6665 5863† 5464†
LV dP/dtmax, mmHg/s 1,7346175 2,9916202† 4,8326377† 1,6216325 3,8106355† 5,3276550†
CPF, ml/min 2163 2563† 2863† 2063 2963† 2964†
CO, l/min 2.360.1 2.660.2 2.960.3† 2.260.2 2.860.2 3.360.3†
Values are means 6 SE. HR, heart rate; SAP, systolic aortic pressure; DAP, diastolic aortic pressure; LV dP/dtmax, left ventricular
contractility; CPF, coronary plasma flow; CO, cardiac output. *P , 0.05, †P , 0.01, compared with baseline.
Fig. 4. Regression analysis of relationship between responses of
maximum 1st derivative of left ventricular pressure (LV dP/dtmax)
and NE concentrations in arterial blood and MIF to infusion of NE.
LV dP/dtmax data are presented as percentages of baseline value; NE
concentrations are presented as changes from baseline (DNE) in
nmol/l. n, Carotid artery (slope 5 6.1 6 1.2, r2 5 0.42); r, MIF LAD
region (slope 5 48.5 6 10.0, r2 5 0.38). Dotted lines indicate 95%
confidence limits. Data are presented for 8 animals.
Fig. 5. NE response to an intracoronary infusion of tyramine. l,
Carotid artery; n, coronary vein; r, MIF LAD region; s, MIF LAD
region under U1 blockade; 3, MIF LCX region. *P , 0.05; **P , 0.01
compared with baseline. Data are presented as means 6 SE for 4
animals.
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though the two probes were placed no more than 1 cm
apart, no interprobe interference was observed. Basal
MIF NE concentrations increased more than sixfold
during U1 inhibition, whereas the increases in MIF NE
concentration due to infusion of NE were also markedly
augmented. Local U1 inhibition in the LAD probe with
DMI increased the DMIF/DA ratio to 0.21–0.36. Espe-
cially under U1 blockade, the DMIF/DA ratio for unla-
beled NE is likely to be affected by NE that is released
by or has leaked from the neurons. Considering this
artifact, our results with DMI are quite comparable to
the MIF/A ratio under U1 blockade as estimated by
Cousineau et al. (8). From the differences in the
DMIF/DA ratios measured in the probes with and
without U1 inhibition, we calculated that 67 6 5% of
MIF NE is removed by U1 (Eq. 3). This value is in close
agreement with values reported for the rabbit (10) but
is lower than those observed in the human myocardium
(12, 19).
As expected, because Iso is not taken up by U1,
similar MIF Iso concentrations were measured in the
probes with and without the U1 inhibitor DMI. The
DMIF/DAratios for Iso were very similar to the DMIF/DA
ratios for NE during the high infusion rate of NE and
local inhibition of U1 by DMI.
Because Iso is not taken up by U1, the difference in
removal of NE and Iso over a certain vascular bed has
been proposed to be a useful measurement of U1
activity (19, 20). Although there is some debate about
the validity of the comparison of the pharmacokinetics
of Iso and NE during U1 blockade (8, 9), the present
findings suggest that such an approach will indeed
provide a reliable estimation of U1 activity. Despite
similar extractions of NE, the extraction of Iso in the
porcine heart (24%) was considerably higher than that
reported for the human heart (14%). This difference in
extraction suggests that the cardiac extraneuronal
uptake of NE is more important in the porcine than in
the human heart. As proposed by Goldstein et al. (19),
the proportionate fractional tissue removal of NE by U1
can be calculated by subtracting the percent removal of
Iso from the percent removal of NE and dividing this
difference by the percent removal of NE. With the
application of this equation in the present study, it
appears that ,66% of NE in the porcine myocardium is
removed by U1. Although considerably lower than the
value reported for the human heart (82%), this value
agrees well with the proportionate fractional tissue
removal of NE by U1 derived from the differences in the
DMIF/DA ratios with and without local U1 inhibition.
Because of the active U1 of NE in the myocardium,
the MIF concentration of NE during systemic NE
infusions remained relatively low compared with the
arterial NE concentration. This explains why the rela-
tionship between LV dP/dtmax and changes in MIF NE
concentration was much steeper than the relationship
between LV dP/dtmax and changes in arterial NE concen-
tration. Accordingly, because Iso is not taken up by U1,
the difference in relationships between LV dP/dtmax and
interstitial or arterial Iso concentrations during Iso
infusions was less distinct.
Studies performed in humans and dogs have shown
that ,5% of the NE that is released into the myocardial
interstitium spills over into the circulation (22). In the
present study, the calculated proportional spillover
(,15%) was considerably higher. Because cardiac spill-
over in our experiments is similar to the value mea-
sured in dogs (14), it seems likely that proportional
spillover was relatively high because the calculated
uptake of NE was relatively low. As shown in Eq. 6, the
calculated uptake of NE strongly depends on the ratio
of RA to RMIF. Although microdialysis is a more direct
technique for measuring interstitial NE concentrations
than the estimates based on the isotope dilution tech-
nique, it will only provide information about the mean
interstitial NE concentration and not about the concen-
tration at sites of release. Because of the downward
concentration gradient of NE from the site of entry in
the interstitial fluid to the sites of uptake, RMIF based
on the mean interstitial NE concentration during sys-
temic infusion of NE will be higher than RMIF at the
sites where uptake of NE takes place. On the basis of
Eq. 6, overestimation of RMIF will lead to the underesti-
mation of the calculated uptake of NE.
In conclusion, microdialysis is a valuable tool for
measuring as well as modifying local sympathetic
activity. The present in vivo experiments largely con-
firm the information about NE kinetics obtained by
more indirect methods. We conclude that U1 as well as
extraneuronal uptake, and not an endothelial barrier,
are the principal mechanisms underlying the concentra-
tion gradient of NE between the interstitial and intra-
vascular compartments in the porcine heart.
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